Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921000995> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2921000995 abstract "Background GESIDA 2018, the national guideline of AIDS in Spain, recommends, in the initial antiretroviral treatment (HAART) in adults infected with HIV, to use a simple target regime (STR) to favour adherence. Purpose To analyse how naive HIV treatment has changed over the years both in economic aspects and in usual clinical practice. Material and methods Longitudinal and descriptive observational study of the series of cases that began during the period January 2013 – September 2018 with antiretrovirals, naive patients only.The data have been extracted from the electronic medical record through the DRAGOAE and Farmatools program, are collected in an Excel spreadsheet and descriptive statistics are then made.The main variables under study were: initial antiretroviral treatment, patient cost per year and date of treatment initiation. Results During this study period, 841 naive patients started treatment. The patients who started per year from 2013 to 2017 were: 105, 180, 140, 146 and 170, respectively. The total annual cost of HAART was: €767,966.83, €1,339,510.52, €1,017,660.24, €1,051,474.85 and €1,122,105,72, respectively. From January to September 2018, 100 patients started antiretroviral treatment and the total cost has been €584,434.94.The average cost per patient and year from 2013 to 2018 was: €7,313.96, €7,441.72, €7,269, €7,201.88, €6,600.62 and €5,844.35, respectively. The treatments most frequently prescribed in the years 2013 to 2018 were: 2013: emtricitabine/tenofovir–disoproxil/rilpivirine (FTC/TDF/RPV) (31%), emtricitabine/tenofovir–disoproxil/efavirenz (FTC/TDF/EFV) (24%) and darunavir/ritonavir (DRV/r) + FTC/TDF (23%). 2014: FTC/TDF/RPV (30%), DRV/r+FTC/TDF (25%) and FTC/TDF/EFV (11%). 2015: abacavir/lamivudine/dolutegravir (ABC/3TC/DLG) (23%), FTC/TDF/RPV (16%), emtricitabine/tenofovir–disoproxil/elvitegravir/cobicistat (FTC/TDF/EVG/COBI) (13%) and FTC/TDF+DLG (13%). 2016: ABC/3TC/DLG (30%), FTC/TDF/EVG/COBI (19%) and FTC/TDF+DLG (16%). 2017: ABC/3TC/DLG (29%), emtricitabine/tenofovir–alafenamide/elvitegravir/cobicistat (FTC/TAF/EVG/COBI) (27%) and FTC/TDF+DLG (19%). 2018: ABC/3TC/DLG (28%), FTC/TDF+DLG (26%) and FTC/TAF/EVG/COBI (20%). Conclusion The integrase inhibitors (DLG and EVG) have become the third drug of choice in the HAART of the naive patients. Moving to IPs and NNRTIs,the combination ABC/DLG/3TC is the most prescribed since 2015, and it is the most cost-effective STR in Spain. The average cost per patient has decreased by €1500/year on average compared to 2014. This is due to the high use of ABC/DLG/3TC and the current low cost of the combination FTC/TDF. References and/or acknowledgements To my service. No conflict of interest." @default.
- W2921000995 created "2019-03-22" @default.
- W2921000995 creator A5008461730 @default.
- W2921000995 creator A5025728177 @default.
- W2921000995 creator A5029135402 @default.
- W2921000995 creator A5030552012 @default.
- W2921000995 creator A5031552862 @default.
- W2921000995 creator A5033055030 @default.
- W2921000995 creator A5061329864 @default.
- W2921000995 creator A5062012854 @default.
- W2921000995 creator A5087875823 @default.
- W2921000995 date "2019-03-01" @default.
- W2921000995 modified "2023-10-17" @default.
- W2921000995 title "4CPS-087 Evolution over time of antiretrovirals" @default.
- W2921000995 doi "https://doi.org/10.1136/ejhpharm-2019-eahpconf.236" @default.
- W2921000995 hasPublicationYear "2019" @default.
- W2921000995 type Work @default.
- W2921000995 sameAs 2921000995 @default.
- W2921000995 citedByCount "0" @default.
- W2921000995 crossrefType "proceedings-article" @default.
- W2921000995 hasAuthorship W2921000995A5008461730 @default.
- W2921000995 hasAuthorship W2921000995A5025728177 @default.
- W2921000995 hasAuthorship W2921000995A5029135402 @default.
- W2921000995 hasAuthorship W2921000995A5030552012 @default.
- W2921000995 hasAuthorship W2921000995A5031552862 @default.
- W2921000995 hasAuthorship W2921000995A5033055030 @default.
- W2921000995 hasAuthorship W2921000995A5061329864 @default.
- W2921000995 hasAuthorship W2921000995A5062012854 @default.
- W2921000995 hasAuthorship W2921000995A5087875823 @default.
- W2921000995 hasBestOaLocation W29210009951 @default.
- W2921000995 hasConcept C126322002 @default.
- W2921000995 hasConcept C142462285 @default.
- W2921000995 hasConcept C142724271 @default.
- W2921000995 hasConcept C159047783 @default.
- W2921000995 hasConcept C187212893 @default.
- W2921000995 hasConcept C23131810 @default.
- W2921000995 hasConcept C2522874641 @default.
- W2921000995 hasConcept C2777869810 @default.
- W2921000995 hasConcept C2778723075 @default.
- W2921000995 hasConcept C2779344132 @default.
- W2921000995 hasConcept C2779778239 @default.
- W2921000995 hasConcept C2780182762 @default.
- W2921000995 hasConcept C2781432083 @default.
- W2921000995 hasConcept C2993143319 @default.
- W2921000995 hasConcept C3013748606 @default.
- W2921000995 hasConcept C3019165603 @default.
- W2921000995 hasConcept C3020491458 @default.
- W2921000995 hasConcept C512399662 @default.
- W2921000995 hasConcept C71924100 @default.
- W2921000995 hasConceptScore W2921000995C126322002 @default.
- W2921000995 hasConceptScore W2921000995C142462285 @default.
- W2921000995 hasConceptScore W2921000995C142724271 @default.
- W2921000995 hasConceptScore W2921000995C159047783 @default.
- W2921000995 hasConceptScore W2921000995C187212893 @default.
- W2921000995 hasConceptScore W2921000995C23131810 @default.
- W2921000995 hasConceptScore W2921000995C2522874641 @default.
- W2921000995 hasConceptScore W2921000995C2777869810 @default.
- W2921000995 hasConceptScore W2921000995C2778723075 @default.
- W2921000995 hasConceptScore W2921000995C2779344132 @default.
- W2921000995 hasConceptScore W2921000995C2779778239 @default.
- W2921000995 hasConceptScore W2921000995C2780182762 @default.
- W2921000995 hasConceptScore W2921000995C2781432083 @default.
- W2921000995 hasConceptScore W2921000995C2993143319 @default.
- W2921000995 hasConceptScore W2921000995C3013748606 @default.
- W2921000995 hasConceptScore W2921000995C3019165603 @default.
- W2921000995 hasConceptScore W2921000995C3020491458 @default.
- W2921000995 hasConceptScore W2921000995C512399662 @default.
- W2921000995 hasConceptScore W2921000995C71924100 @default.
- W2921000995 hasLocation W29210009951 @default.
- W2921000995 hasOpenAccess W2921000995 @default.
- W2921000995 hasPrimaryLocation W29210009951 @default.
- W2921000995 hasRelatedWork W1858310829 @default.
- W2921000995 hasRelatedWork W2015834688 @default.
- W2921000995 hasRelatedWork W2032047809 @default.
- W2921000995 hasRelatedWork W2097245338 @default.
- W2921000995 hasRelatedWork W2268543369 @default.
- W2921000995 hasRelatedWork W2323941313 @default.
- W2921000995 hasRelatedWork W2341618777 @default.
- W2921000995 hasRelatedWork W2477756378 @default.
- W2921000995 hasRelatedWork W2560580331 @default.
- W2921000995 hasRelatedWork W2921000995 @default.
- W2921000995 isParatext "false" @default.
- W2921000995 isRetracted "false" @default.
- W2921000995 magId "2921000995" @default.
- W2921000995 workType "article" @default.